�Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
(Nasdaq: ONXX) announced the companies have begun enrolling patients
in the STORM Sorafenib as Adjuvant Treatment in the Prevention of
Recurrence of Hepatocellular Carcinoma trial. The randomized, double blind,
placebo-controlled Phase 3 sketch is evaluating Nexavar(R) (sorafenib)
tablets as adjuvant discussion, which is treatment next surgery or
local radiation, for patients with hepatocellular carcinoma (HCC), or
elemental liver cancer.
"Nexavar is the only systemic therapy with proven efficacy and
tolerability in HCC across multiple affected role populations," % 31, 2007,
filed with the Securities and Exchange Commission under the heading "Risk
Factors" and Onyx's Quarterly Reports on Form 10-Q for a more elaborated
description of such factors. Readers are cautioned not to situation undue
trust on these forward-looking statements that talk only as of the date
of this release. Onyx undertakes no obligation to update publicly whatever
forward-looking statements to reflect new information, events, or
circumstances afterwards the date of this release except as compulsory by law.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer
HealthCare Pharmaceuticals, Inc.
References
(1) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and
Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress,
Lyon, 2004. Available at: hTTP://www-dep.iarc.fr. Accessed May 2008.
(2) 2005 Cancer Register System (CRS) annual report,
http://crs.cph.ntu.edu.tw/crs_c/annual.html. Accessed May 12, 2008.
(3) Del Pozo AC, Lopez P. Management of hepatocellular carcinoma. Clin
Liver Dis 2007 May;11(2):305-21.
Onyx Pharmaceuticals, Inc
http://www.onyx-pharm.com
View do drugs information on Nexavar.
More information
